MENU
Alnylam

New Pre-Clinical Data on ALN-PCSsc and ALN-ANG Presented at AHA

We presented new pre-clinical data with RNAi therapeutic programs for cardiovascular disease: ALN-PCSsc, an RNAi therapeutic targeting PCSK9 for the treatment of hypercholesterolemia; and ALN-ANG, an RNAi therapeutic targeting ANGPTL3 for the treatment of genetic forms of mixed hyperlipidemia and severe hypertriglyceridemia. These data were presented at the American Heart Association (AHA) Scientific Sessions held November 16 – 20, 2013 in Dallas, Texas. The data showed that subcutaneous administration of ALN-PCSsc led to an up to 95% knockdown of plasma PCSK9 and an up to 67% reduction of low density lipoprotein cholesterol (LDL-C) – in the absence of statin co-administration. In addition, new results for ALN-ANG demonstrated a greater than 95% reduction of triglycerides and greater than 85% reduction of LDL-C in a rodent model of mixed hyperlipidemia.



We believe these results with ALN-PCSsc support a highly competitive target product profile. Furthermore, the pre-clinical results with ALN-ANG phenocopy the human genetics for loss of function in ANGPTL3, and are supportive of our efforts to advance this new RNAi therapeutic program into later stages of pre-clinical development.